b) What were the implications for you of the transition of a number of patients receiving ongoing treatment as a result of the tender outcomes in 2012? Did you encounter any substantial difficulties? How satisfied were you with the planning and communications concerning that transition period? Do you have any suggestions for how any product brand transition could be managed better in future? 5. VALUABLE PRODUCT CHARACTERISTICS Please indicate whether particular characteristics of IVIg/SCIg products provide significant value to you, and why, as below: Characteristic Area of value Comments Scope of clinical registered product indications management patient convenience/ quality of life not an important value aspect Viral inactivation clinical processes or product other management manufacturing patient aspects (please convenience/ specify) quality of life not an important value aspect Differences in clinical concentration product Please comment management on different patient available convenience/ concentrations quality of life where relevant: not an important IVIg - 5% value aspect
b) What were the implications for you of the transition of a number of patients receiving ongoing treatment as a result of the tender outcomes in 2012? Did you encounter any substantial difficulties? How satisfied were you with the planning and communications concerning that transition period? Do you have any suggestions for how any product brand transition could be managed better in future? 5. VALUABLE PRODUCT CHARACTERISTICS Please indicate whether particular characteristics of IVIg/SCIg products provide significant value to you, and why, as below: Characteristic Area of value Comments Scope of registered indications clinical product management patient convenience/ quality of life not an important value aspect Viral inactivation processes or other manufacturing aspects (please specify) clinical product management patient convenience/ quality of life not an important value aspect Differences in concentration Please comment on different available concentrations where relevant: IVIg - 5% clinical product management patient convenience/ quality of life not an important value aspect
supply-%20imported-ig-stakeholder-consultation.docx